Lennox-Gastaut Syndrome
Lennox-Gastaut Syndrome (LGS) is a rare, severe form of epilepsy that affects fewer than six in 100,000 people in the UK.1,2,3 It typically begins in childhood and often continues into adulthood. LGS is characterised by multiple seizure types, including tonic, atonic and atypical absence seizures.3,4,5,6
Beyond seizures, LGS can affect cognitive development, learning, language and communication.5,6 Many people experience significant lifelong challenges, and the condition can place a substantial emotional, physical and practical burden on families and caregivers.7
What is Lennox-Gastaut Syndrome (LGS)?
Lennox-Gastaut Syndrome (LGS) is a rare, severe form of epilepsy that typically begins in early childhood and persists into adulthood.4 It is characterised by multiple types of seizures, cognitive impairment and abnormalities on electroencephalogram (EEG) recordings.5
How common is LGS?
LGS is a rare form of epilepsy, affecting fewer than six in 100,000 people in the UK. It accounts for around 1-5% of childhood epilepsy cases.1,2
Although LGS accounts for only a small proportion of epilepsy diagnoses, it is associated with a disproportionate share of epilepsy-related disability because of its treatment-resistant seizures and associated cognitive and behavioural difficulties.6,8
What are the symptoms of LGS?
People living with LGS often experience multiple seizure types, most commonly tonic seizures (stiffening of the body), atonic seizures (sudden loss of muscle tone, sometimes referred to as "drop attacks"), and atypical absence seizures, which can affect awareness and responsiveness. Seizures may occur frequently and can increase the risk of injury, affecting many aspects of daily life.6
What is living with LGS like?
Living with LGS means more than seizure control – its challenges can affect education, relationships, independence and participation in everyday activities. LGS impacts a person’s cognitive development, learning, language and communication. Many people experience developmental delays and varying degrees of intellectual disability, as well as severe personality and behavioural disorders such as hyperactivity, aggression, autistic traits, and in some cases, the development of psychosis over time.5,6,9
Although LGS usually begins during childhood, it often persists throughout life. While seizure patterns may change over time, many people continue to experience them, as well as cognitive difficulties and functional impairments into adulthood. As a result, people living with LGS may need life-long, ongoing medical, social and practical support.10
LGS not only impacts the patient, but can also affect their entire family ‒ parents, caregivers and siblings ‒ in multiple ways. They often experience physical exhaustion, disrupted sleep and feelings of isolation, which can lead to depression and social and private life problems. Besides the physical and psychological impact, caring for a person diagnosed with LGS can also be associated with financial concerns.7
What causes LGS?
LGS can be caused by a range of underlying conditions:1
- Genetic conditions
- Structural or developmental abnormalities in the brain
- Complications during childbirth, such as oxygen deprivation
- Infections in infancy, such as meningitis
- A severe head injury resulting in brain damage
- Metabolic disorders
However, in up to a third of people diagnosed with LGS, no clear cause can be identified for the onset of symptoms.11
Can LGS be cured?
There is currently no cure for LGS. Treatment focuses on reducing seizures, managing symptoms and helping people achieve the best possible quality of life, through appropriate ongoing care and support.8
What are the unmet needs of people living with LGS?
Despite the availability of treatment options, many people living with LGS continue to experience uncontrolled or difficult-to-treat seizures.8 The condition is frequently associated with significant cognitive, behavioural and developmental challenges, creating a substantial burden for both patients and caregivers.7
There remains a need for improved seizure control, earlier recognition and diagnosis, coordinated specialist care, and better support for families affected by the condition. At UCB, improving the quality of life for people living with LGS and those who care for them remains a key priority.
Interested in UCB's approach to rare diseases?
The Aspire4Rare Framework is a global policy guidance framework developed by UCB and a multidisciplinary panel of rare disease experts. It aims to help governments, policymakers, healthcare systems, researchers, and patient organisations strengthen health systems for the estimated 300 million people living with rare diseases worldwide, offering a practical framework, measurable outcomes, and examples of good practice to guide rare disease policy development and implementation.
To learn more about the Lennox-Gastaut Syndrome community and available support, head to Epilepsy Action and Young Epilepsy.
References
1. Epilepsy Action. Lennox Gastaut Syndrome. Available at: https://www.epilepsy.org.uk/info/Syndromes/lennox-gastaut-Syndrome Last accessed: October 2026
2. Young Epilepsy. Rare, but real: a mother’s story of Lennox-Gastaut Syndrome. Available at: https://www.youngepilepsy.org.uk/story/rare-real-mothers-story-of-lennox-gastaut-Syndrome Last accessed: October 2026
3. National Institute for Health and Care Excellence (NICE), 2023. Final scope for the evaluation of fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over. Technology appraisal guidance TA1050. London: NICE. Available at: https://www.nice.org.uk/guidance/ta1050/documents/final-scope Last accessed: October 2026
4. Epilepsy Ireland. Lennox-Gastaut Syndrome. Available at: https://www.epilepsy.ie/content/lennox-gastaut-Syndrome Last accessed: October 2026
5. Amrutkar CV, Riel-Romero RM. Lennox Gastaut Syndrome. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532965/
6. National Organization for Rare Diseases (NORD). LGS. Available at: https://rarediseases.org/rare-diseases/lennox-gastaut-Syndrome Last accessed October 2026
7. Gibson PA. Lennox-Gastaut Syndrome: impact on the caregivers and families of patients. J Multidiscip Healthc. 2014 Oct 4;7:441-8. doi: 10.2147/JMDH.S69300.
8. Cross JH, et al. Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations. Front Neurol. 2017;8:505. Published 2017 Sep 29.
9. NSWG. Lennox Gastaut Syndrome (LGS). Available at: https://www.schn.health.nsw.gov.au/epilepsy-clinician-handbook/syndromes/lennox-gastaut-syndrome-lgs-epilepsy-clinician-handbook Last accessed: October 2026
10. Kerr M, et al. Evolution and management of Lennox-Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue? Epileptic Disord. 2011 May;13 Suppl 1:S15-26. doi: 10.1684/epd.2011.0409.
11. NINDS. Lennox-Gastaut Syndrome. Available at: https://www.ninds.nih.gov/health-information/disorders/lennox-gastaut-syndrome Last accessed: October 2026
Last updated: October 2026
IE-DA-2600394